biostudies-literatureDuarte Romero BLNational Health and Medical Research Council357https://www.ebi.ac.uk/biostudies/studies/S-EPMC12845487biostudies-literatureUnknown18(2)<b>Background/Objectives</b>: Observational studies have found inverse associations between 25-hydroxyvitamin D concentration and risk of hypertension, hypercholesterolemia and type 2 diabetes (T2D). More robust evidence from large-scale randomized controlled trials, however, is limited or inconclusive. <b>Methods</b>: The D-Health Trial (N = 21,315) is a randomized, double-blind, placebo-controlled trial of supplementation with monthly doses of 60,000 international units of oral vitamin D₃, conducted in Australians aged 60-84 years. Commencing treatment with anti-hypertensive, lipid-modifying, or anti-diabetic drugs was used as a surrogate for incident hypertension, hypercholesterolemia, and T2D, respectively. Outcomes were ascertained via linkage with the Australian PharmaceutNutrientsEffect of Vitamin D Supplementation on Cardiometabolic Outcomes in Older Australian Adults-Results from the Randomized Controlled D-Health Trial.PMC12845487GNT1060183GNT1155413GNT1173346GNT1120682GNT1197958GNT1046681English DRNa RMcLeod DSAHartel GPham HWebb PMNeale REWhiteman DCBaxter CVenn AJKimlin MGRoss TDuarte Romero BLvan der Pols JCWaterhouse MEbeling PRArmstrong BKfalseEffect of Vitamin D Supplementation on Cardiometabolic Outcomes in Older Australian Adults-Results from the Randomized Controlled D-Health Trial.<b>Background/Objectives</b>: Observational studies have found inverse associations between 25-hydroxyvitamin D concentration and risk of hypertension, hypercholesterolemia and type 2 diabetes (T2D). More robust evidence from large-scale randomized controlled trials, however, is limited or inconclusive. <b>Methods</b>: The D-Health Trial (N = 21,315) is a randomized, double-blind, placebo-controlled trial of supplementation with monthly doses of 60,000 international units of oral vitamin D₃, conducted in Australians aged 60-84 years. Commencing treatment with anti-hypertensive, lipid-modifying, or anti-diabetic drugs was used as a surrogate for incident hypertension, hypercholesterolemia, and T2D, respectively. Outcomes were ascertained via linkage with the Australian Pharmaceut2026-01-01T00:00:00Z2026 Jan2026-06-13T03:26:19.321Z2026-06-13T03:12:48.721ZS-EPMC128454874159997110.3390/nu18020357